Ventyx Biosciences, Inc. (VTYX)
$14.00+0.00%Close
BUYBULL · day 36
Key stats
- Market cap
- $1.0B
- Beta
- 1.27
- P/E (TTM)
- -20.00
- 1W
- +0.21%
- 1M
- +0.65%
- vs SPY 1W
- -0.95%
- vs SPY 1M
- -2.35%
Industry peers
FMP comparable companies · ranked by market cap
- ABSIBUYAbsci Corporation$1.5BCRISISQ 3$8.94+13.65%
- KALVKalVista Pharmaceuticals, Inc.$1.4B$27.00
- RIGLBUYRigel Pharmaceuticals, Inc.$901MBULLQ 9$48.72+0.74%
- MLTXSELLMoonLake Immunotherapeutics$890MCRISISQ -0$10.58+2.27%
- CRVSSELLCorvus Pharmaceuticals, Inc.$859MCRISISQ 13$10.21+3.04%
- VSTMBUYVerastem, Inc.$713MRECOVERYQ 4$8.11+3.33%
- OLMASELLOlema Pharmaceuticals, Inc.$683MCRISISQ -1$7.82+0.00%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on VTYX?
- LOPJLB’s latest quantitative signal on Ventyx Biosciences, Inc. (VTYX) is BUY in a BULL regime. Signals are updated daily.
- What market regime is VTYX in?
- Ventyx Biosciences, Inc. (VTYX) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Ventyx Biosciences, Inc. (VTYX) do?
- Ventyx Biosciences, Inc. is a biopharmaceutical company in the clinical development phase, specializing in the creation of small molecule therapeutics for inflammatory and autoimmune disorders. The company's primary investigational drug, VTX958, a tyrosine kinase type 2 (TYK2) inhibitor, is currently undergoing Phase I clinical trials. This compound aims to address a range of immune-mediated co…